Bellevue Life Sciences Acquisition's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bellevue Life Sciences Acquisition's ROA in the second quarter of 2026?
Bellevue Life Sciences Acquisition Corp recorded a cumulative net loss of $-15 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -8.68%.

However, within the Healthcare sector 286 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3187, from total ROA ranking in the first quarter of 2026 at 3817.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-9.87 %	-1.3 %	7371.64 %	783.19 %	816.66 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-15	-19	-27	-22	-19
Return On Assets (TTM)	-8.68 %	-10.84 %	-15.29 %	-16.4 %	-19.84 %
BLAC's Total Ranking	# 3187	# 3817	# 3459	# 3605	# 3742
Total Assets (TTM) in million	167	172	172	177	185
Seq. Total Assets Change	-3 %	-0.18 %	-2.78 %	-4.26 %	6.22 %
Seq. Net Income Change	-	-	-	-	-

BLAC's 5 Years Annual ROA >> Back to BLAC Management Effectiveness >> Compare BLAC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 90
Sector	# 287
Overall	# 3089

Return On Assets Statistics
High	Average	Low
2.04 %	-9.53 %	-25.22 %
(Dec 31 2023)		(Mar 31 2025)

Financial Statements
Bellevue Life Sciences Acquisition's Assets	$ 167 million	BLAC's Balance sheet
Bellevue Life Sciences Acquisition's Income	$ -1 million	Quarterly BLAC's Income Statement
BLAC's Income by Division		See BLAC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	7371.64 %	-91.82 %	2195.82 %	-	-
Total Assets in million	172	2	28	1	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-27	-2	0	0	0
Annual Return On Assets	-15.72 %	-104.68 %	1.43 %	-2.89 %	-

BLAC's 5 Years Annual ROA >> Back to BLAC Management Effectiveness >> Compare BLAC ROA to its Competitors

More Return On Assets Ratios
BLAC's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BLAC's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BLAC's Competitors
Subscribers only: Roa for Bellevue Life Sciences Acquisition's Suppliers
Subscribers only: Return On Assets for BLAC's Customers

You may also want to know
BLAC's Roi	BLAC's Inventory Turnover Ratio	BLAC's Growth Rates	BLAC's Dividend Comparisons
	BLAC's Profitability Ratios	BLAC's Asset Turnover Ratio	BLAC's Dividend Growth
BLAC's Roe	BLAC's Valuation Ratios	BLAC's Financial Strength Ratios	BLAC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-17T17:21:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.